Next-generation technology at Point of Care

With society reopaened in many countries, non-COVID-19 viruses are potentially circulating again.
The causes and types of respiratory tract infections (RTIs) are wide and can be difficult to discriminate by symptoms alone.
Rapid identification of the underlying cause of respiratory illness can guide appropriate clinical decisions, helping to improve patient outcomes and patient workflows

for more information



Multiple tests, one Platform

The next-generation high sensitivity microfluidic technology on the LumiraDx Platform contains some of the key assays for respiratory pathogens and biomarkers* on one platform, helping identify and differentiate the underlying cause of respiratory illness and helping inform treatment decisions at the point of care.


For more information about the tests

Get in touch to find out more:

Fast, accurate lab-comparable results START HERE

SARS-CoV-2 & Flu A/B

Is it COVID-19? Is it Flu? Lab-comparable results in minutes for patients suspected of COVID-19 or Flu


High sensitivity antigen test: potentially verify COVID-19 quickly, helping to prevent further spread of infection

SARS-CoV-2 Ag Pool

Quickly and easily scale up COVID-19 testing: low-cost, high sensitivity diagnostic screening solution


Rapidly identify individuals with an adaptive immune response to COVID-19, indicating recent or prior infection.


Reliable, quantitative results drive well-informed decisions on antibiotic prescribing at the point of care

The Age of Microfluidics

Lab-comparable performance

Next-generation, microfluidic technology providing lab-comparable performance

Rapid actionable results

Results in minutes guiding appropriate treatment decisions and pathways at community and POC settings, enabling improved patient flow

Efficiencies at the POC

Replace multiple POC systems with a single platform, increasing efficiency through reduced training, equipment, maintenance and test supplies

Broad menu – One integrated Platform

Capable of covering infectious disease, cardiovascular disease, diabetes and coagulation disorders

LumiraDx Connect

Connect Manager Cloud-based services provide all capabilities to remotely manage and configure Instruments, view test results and simplify workgroup provisioning. Can be used with mobile, tablet or PC.

EHR Connect enables the transfer of results from the instrument

The LumiraDx Platform Instrument can be used in three modes:

  • Standalone
  • Managed
  • EHR Connected

*Represents assays available. Not all products are available in all countries and regions.
Copyright ©2022 LumiraDx UK LTD. All rights reserved worldwide. LumiraDx and Flame logo are protected trademarks of LumiraDx International LTD. Full details of these and other registrations of LumiraDx can be found at All other trademarks are the property of their respective owners. Product not available in all countries and regions.